AC
FDMT icon

AXQ Capital’s 4D Molecular Therapeutics FDMT Stock Holding History

AXQ Capital’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$186K Buy
+13,964
New +$136K 0.02% 738
2026
Q1 		– Sell
-30,755
Closed -$231K – 1083
2025
Q4 		$231K Buy
30,755
+17,876
+139% +$181K 0.05% 516
2025
Q3 		$112K Buy
+12,879
New +$77K 0.04% 512
2025
Q1 		– Sell
-19,753
Closed -$110K – 549
2024
Q4 		$110K Buy
+19,753
New +$155K 0.05% 375

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

AXQ Capital's FDMT Position: Q2 2026 in Review

AXQ Capital opened a new position in 4D Molecular Therapeutics (FDMT) in Q2 2026: 13,964 shares worth $186K. The stake represents 0.02% of the portfolio and ranks #738 among its holdings. This is a return to the name: AXQ Capital previously reported a position in FDMT as recently as Q4 2025.

AXQ Capital first reported a position in FDMT in Q4 2024 and has held it in 4 quarters since. The position peaked at $231K in Q4 2025. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • AXQ Capital held 13,964 shares of 4D Molecular Therapeutics worth $186K as of Q2 2026.
  • 4D Molecular Therapeutics was a new AXQ Capital position in Q2 2026.
  • 4D Molecular Therapeutics made up 0.02% of AXQ Capital's portfolio in Q2 2026, its #738 holding.
  • AXQ Capital first reported a position in 4D Molecular Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • AXQ Capital's 4D Molecular Therapeutics position peaked at $231K in Q4 2025.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on AXQ Capital's 13F filing for Q2 2026, filed 6 Aug 2026.